bms955176
Small moleculeexperimental
Clinical trial activity
11 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01803074)
Timeline
Indications
Studied for
Mechanism of action
- HIV-1 proteaseINHIBITOR
HIV-1 protease inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bms955176
- bms-955176
- bms-955176
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02715479 | Phase 1 | Apr 1, 2016 | GlaxoSmithKline, ViiV Healthcare |
| NCT02608918 | Phase 1 | Nov 1, 2015 | Bristol-Myers Squibb, Senopsys, LLC |
| NCT02578277 | Phase 1 | Nov 1, 2015 | Bristol-Myers Squibb |
| NCT02576119 | Phase 1 | Oct 1, 2015 | GlaxoSmithKline, ViiV Healthcare |
| NCT02386098 | Phase 2 | Jul 8, 2015 | GlaxoSmithKline, ViiV Healthcare |
| NCT02415595 | Phase 2 | May 12, 2015 | GlaxoSmithKline, ViiV Healthcare |
| NCT02273947 | Phase 1 | Oct 23, 2014 | GlaxoSmithKline, ViiV Healthcare |
| NCT02206711 | Phase 1 | Aug 1, 2014 | Bristol-Myers Squibb |
| NCT02157467 | Phase 1 | Jun 1, 2014 | Bristol-Myers Squibb, MRA Clinical Research |
| NCT02095886 | Phase 1 | Mar 1, 2014 | Bristol-Myers Squibb |
| NCT01803074 | Phase 2 | Apr 1, 2013 | GlaxoSmithKline, ViiV Healthcare |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 0 | 2 | 2013 |
| ViiV Healthcare | For profit | 6 | 6 | 2 | 2013 |
| Bristol-Myers Squibb | For profit | 5 | 5 | 1 | 2014 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Senopsys, LLC | For profit | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1